Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice

Journal of Neurochemistry

Volumn 136, Issue 1, 2016, Pages 194-204

  Miyazaki, Ikuko ^a   Murakami, Shinki ^a,b   Torigoe, Nao ^a   Kitamura, Yoshihisa ^a   Asanuma, Masato ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b SAIDO Co   (Japan)

Author keywords

antioxidant; astrocytes; neuroprotection; Parkinson's disease; xCT

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; CYSTEINE GLUTAMATE EXCHANGE TRANSPORTER PROTEIN; ETIRACETAM; GLUTATHIONE; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; NEUROPROTECTIVE AGENT; PIRACETAM; SLC7A11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; EMBRYO; MALE; NERVE DEGENERATION; NERVE INJURY; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOUSE; PARKINSONIAN DISORDERS; PREGNANCY; PROCEDURES; SPRAGUE DAWLEY RAT;

AMINO ACID TRANSPORT SYSTEM Y+; ANIMALS; ASTROCYTES; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; FEMALE; MALE; MICE; MICE, INBRED ICR; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PIRACETAM; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84951906427     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13405     Document Type: Article

References (45)

1. Asanuma M., Miyazaki I., Diaz-Corrales F. J., Kimoto N., Kikkawa Y., Takeshima M., Miyoshi K., and, Murata M., (2010) Neuroprotective effects of zonisamide target astrocyte. Ann. Neurol. 67, 239-249.
2. Bhattacharyya S., Zhang X., Feferman L., Johnson D., Tortella F. C., Guizzetti M., and, Tobacman J. K., (2015) Decline in arylsulfatase B and Increase in chondroitin 4-sulfotransferase combine to increase chondroitin 4-sulfate in traumatic brain injury. J. Neurochem. 134, 728-739.
3. Chounlamountry K., Boyer B., Penalba V., Francois-Bellan A. M., Bosler O., Kessler J. P., and, Strube C., (2015) Remodeling of glial coverage of glutamatergic synapses in the rat nucleus tractus solitarii after ozone inhalation. J. Neurochem. 134, 857-864.
4. Du H., Nie S., Chen G., Ma K., Xu Y., Zhang Z., Papa S. M., and, Cao X., (2015) Levetiracetam ameliorates L-DOPA-Induced dyskinesia in hemiparkinsonian rats inducing critical molecular changes in the striatum. Parkinsons Dis. 2015, 253878.
5. Franklin K. B. J., and, Paxinos G., (1997) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego.
6. Fuks B., Gillard M., Michel P., Lynch B., Vertongen P., Leprince P., Klitgaard H., and, Chatelain P., (2003) Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur. J. Pharmacol. 478, 11-19.
7. Gillard M., Fuks B., Michel P., Vertongen P., Massingham R., and, Chatelain P., (2003) Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur. J. Pharmacol. 478, 1-9.
8. Gower A. J., Hirsch E., Boehrer A., Noyer M., and, Marescaux C., (1995) Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 22, 207-213.
9. Hamby M. E., and, Sofroniew M. V., (2010) Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics 7, 494-506.
10. Hauser R. A., Lyons K. E., McClain T., Carter S., and, Perlmutter D., (2009) Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov. Disord. 24, 979-983.
11. Heneka M. T., Rodriguez J. J., and, Verkhratsky A., (2010) Neuroglia in neurodegeneration. Brain Res. Rev. 63, 189-211.
12. Hill M. P., Bezard E., McGuire S. G., Crossman A. R., Brotchie J. M., Michel A., Grimee R., and, Klitgaard H., (2003) Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov. Disord. 18, 1301-1305.
13. Hill M. P., Ravenscroft P., Bezard E., Crossman A. R., Brotchie J. M., Michel A., Grimee R., and, Klitgaard H., (2004) Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J. Pharmacol. Exp. Ther. 310, 386-394.
14. Kaneko S., Hikida T., Watanabe D., Ichinose H., Nagatsu T., Kreitman R. J., Pastan I., and, Nakanishi S., (2000) Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function. Science 289, 633-637.
15. Kato S., Negishi K., Mawatari K., and, Kuo C. H., (1992) A mechanism for glutamate toxicity in the C6 glioma cells involving inhibition of cystine uptake leading to glutathione depletion. Neuroscience 48, 903-914.
16. Kelsey J. E., and, Neville C., (2014) The effects of the beta-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease. Psychopharmacology 231, 2405-2415.
17. Klitgaard H., Matagne A., Gobert J., and, Wulfert E., (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 353, 191-206.
18. Lee J. M., Shih A. Y., Murphy T. H., and, Johnson J. A., (2003) NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J. Biol. Chem. 278, 37948-37956.
19. Lee H. J., Suk J. E., Patrick C., Bae E. J., Cho J. H., Rho S., Hwang D., Masliah E., and, Lee S. J., (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285, 9262-9272.
20. Lewerenz J., Klein M., and, Methner A., (2006) Cooperative action of glutamate transporters and cystine/glutamate antiporter system Xc- protects from oxidative glutamate toxicity. J. Neurochem. 98, 916-925.
21. Lewerenz J., Albrecht P., Tien M. L., et al,. (2009) Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J. Neurochem. 111, 332-343.
22. Loscher W., Honack D., and, Rundfeldt C., (1998) Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 284, 474-479.
23. Lukyanetz E. A., Shkryl V. M., and, Kostyuk P. G., (2002) Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43, 9-18.
24. Lynch B. A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S. M., Matagne A., and, Fuks B., (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA 101, 9861-9866.
25. Madeja M., Margineanu D. G., Gorji A., Siep E., Boerrigter P., Klitgaard H., and, Speckmann E. J., (2003) Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 45, 661-671.
26. Mena M. A., and, Garcia de Yebenes J., (2008) Glial cells as players in parkinsonism: the "good", the "bad", and the "mysterious" glia. Neuroscientist 14, 544-560.
27. Miyazaki I., Asanuma M., Kikkawa Y., Takeshima M., Murakami S., Miyoshi K., Sogawa N., and, Kita T., (2011) Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity. Glia 59, 435-451.
28. Miyazaki I., Asanuma M., Murakami S., Takeshima M., Torigoe N., Kitamura Y., and, Miyoshi K., (2013) Targeting 5-HT(1A) receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models. Neurobiol. Dis. 59, 244-256.
29. Nevalainen N., Lundblad M., Gerhardt G. A., and, Stromberg I., (2013) Striatal glutamate release in L-DOPA-induced dyskinetic animals. PLoS ONE 8, e55706.
30. Rappold P. M., and, Tieu K., (2010) Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics 7, 413-423.
31. Rascol O., Perez-Lloret S., and, Ferreira J. J., (2015) New treatments for levodopa-induced motor complications. Mov. Disord. 30, 1451-1460.
32. Robinson M. B., (1998) The family of sodium-dependent glutamate transporters: a focus on the GLT-1/EAAT2 subtype. Neurochem. Int. 33, 479-491.
33. Rothstein J. D., Dykes-Hoberg M., Pardo C. A., et al,. (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675-686.
34. Sato H., Nomura S., Maebara K., Sato K., Tamba M., and, Bannai S., (2004) Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation. Biochem. Biophys. Res. Commun. 325, 109-116.
35. Sechi G., Deledda M. G., Bua G., Satta W. M., Deiana G. A., Pes G. M., and, Rosati G., (1996) Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 20, 1159-1170.
36. Shih A. Y., Johnson D. A., Wong G., Kraft A. D., Jiang L., Erb H., Johnson J. A., and, Murphy T. H., (2003) Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J. Neurosci. 23, 3394-3406.
37. Shih A. Y., Erb H., Sun X., Toda S., Kalivas P. W., and, Murphy T. H., (2006) Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. J. Neurosci. 26, 10514-10523.
38. Sofroniew M. V., (2015) Astrocyte barriers to neurotoxic inflammation. Nat. Rev. Neurosci. 16, 249-263.
39. Soria F. N., Perez-Samartin A., Martin A., Gona K. B., Llop J., Szczupak B., Chara J. C., Matute C., and, Domercq M., (2014) Extrasynaptic glutamate release through cystine/glutamate antiporter contributes to ischemic damage. J. Clin. Invest. 124, 3645-3655.
40. Stathis P., Konitsiotis S., Tagaris G., and, Peterson D., (2011) Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 26, 264-270.
41. Tietze F., (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem. 27, 502-522.
42. Ueda Y., Doi T., Nagatomo K., Tokumaru J., Takaki M., and, Willmore L. J., (2007) Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection. Brain Res. 1151, 55-61.
43. Ueda Y., Doi T., Takaki M., Nagatomo K., Nakajima A., and, Willmore L. J., (2009) Levetiracetam enhances endogenous antioxidant in the hippocampus of rats: in vivo evaluation by brain microdialysis combined with ESR spectroscopy. Brain Res. 1266, 1-7.
44. Wang X. F., and, Cynader M. S., (2000) Astrocytes provide cysteine to neurons by releasing glutathione. J. Neurochem. 74, 1434-1442.
45. Wolz M., Lohle M., Strecker K., Schwanebeck U., Schneider C., Reichmann H., Grahlert X., Schwarz J., and, Storch A., (2010) Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J. Neural. Transm. 117, 1279-1286.